Intuitive Surgical: Stellar Q2 Numbers Can't Halt a 12-Bank Price Target Slash
Published on 07/20/2026 at 16:55 | Redaktion boerse-global.de
Intuitive Surgical delivered a second-quarter earnings report that would make most companies envious — $2.89 billion in revenue, a 19% jump from a year ago, adjusted earnings per share of $2.80 that handily beat consensus, and 468 da Vinci systems shipped, 246 of them the latest da Vinci 5 model. Yet within hours, the stock was shedding more than 13% in after-hours trading and gapping down to a fresh 52-week low of 299.60 euros on the Xetra exchange. The disconnect between the numbers and the market's reaction tells a story not about the quarter that was, but about the quarter that is yet to come.
The culprit was a single unchanged line in the company's outlook. Intuitive Surgical reaffirmed its full-year guidance for global da Vinci procedure growth in the range of 13.5% to 15.5%, leaning toward the midpoint. The market had been anticipating a raise, with Bloomberg Intelligence data putting the consensus at 15.3%. Management's decision to hold the line signaled a deceleration ahead — and investors promptly priced in the disappointment. CEO David Rosa pointed to a marked slowdown in the U.S., where procedure volumes grew only 12% in the second quarter, down from 14% in the first. He attributed the softening to shifts in patient insurance coverage tied to the expiration of enhanced ACA premium subsidies, a dynamic that Abbott Laboratories had recently downplayed for the broader med-tech sector. The two diverging reads from industry leaders left analysts parsing the same policy change for very different conclusions.
The market's verdict arrived swiftly. Twelve investment banks slashed their price targets for Intuitive Surgical within a single trading session, even as most maintained their underlying ratings. JPMorgan cut its target to $450 from $550, citing a "flatter" growth trajectory that it said would cap the stock. Mizuho went to $400 from $500, keeping a Hold rating, flagging that demand for ancillary components was beginning to stall. The cuts spanned the whole spectrum: Wells Fargo from $654 to $487, Stifel from $670 to $550, Citigroup from $590 to $500, RBC Capital from $600 to $575, and Bernstein — the most bullish holdout — from $750 to $685, though it stuck with its Outperform call. The common thread: the business itself remains solid, but the growth rate no longer justifies the premium multiple the stock once commanded. Piper Sandler noted that the U.S. procedure growth had decelerated by roughly 200 basis points sequentially, a magnitude that forced even analysts who kept Overweight ratings to pull in their valuation targets.
Should investors sell immediately? Or is it worth buying Intuitive Surgical?
The selling has pushed the shares into oversold territory by technical measures. The 14-day relative strength index dipped to 29.6, a level that historically has preceded snap-back rallies. The stock closed at 302.00 euros, roughly 16% below its 50-day moving average of 359.22 euros and more than 40% off its January record high of 516.50 euros. Yet the gap between the current price and the median analyst target of approximately $558 suggests Wall Street still sees value — provided the U.S. procedure volume stabilizes in the second half. That hinges on whether the insurance-driven lull Rosa described proves temporary or structural. With HCA Healthcare having recently warned of softer surgical demand tied to rising numbers of uninsured patients, the sector-wide headwind is becoming harder to ignore. For Intuitive Surgical, the waiting game has begun.
Ad
Intuitive Surgical Stock: New Analysis - 20 July
Fresh Intuitive Surgical information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
